PTI 188

Drug Profile

PTI 188

Alternative Names: 188Re-PTI-6D2; Anti-melanin monoclonal antibody; PTI-188; PTI-6D2

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Albert Einstein College of Medicine
  • Developer Pain Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Malignant-melanoma(Metastatic disease) in Israel (IV, Infusion)
  • 02 Nov 2010 Pain Therapeutics receives a grant under the US Government's Qualifying Therapeutic Discovery Project Programme to support its research in oncology
  • 26 Mar 2010 Efficacy and adverse events data from two phase I trials in metastatic Malignant melanoma released by Pain Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top